Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetaspHER: Preference for SC vs IV Trastuzumab in HER2+ Metastatic Breast Cancer
NCT01810393Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2013
- Primary completion
- Jul 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in HER2-positive metastatic breast cancer, sponsored by Roche. Started Jun 2013; status: completed.
02
Drugs
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01810393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01810393.